Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q4 2018 Earnings Conference Call - Final Transcript

Feb 26, 2019 • 04:30 pm ET


Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q4 2018 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, and welcome to the Akcea Therapeutics Fourth Quarter and Year-end 2018 Conference Call. As a reminder, this call is being recorded.

I will now turn the call over to Kathleen Gallagher, Akcea's Vice President of Corporate Communications and Investor Relations. Ms. Gallagher, please begin.

Kathleen Gallagher

Thank your, Ashley. Good afternoon, everyone, and thanks for joining us today. With me on today's call are Paula Soteropoulos, our Chief Executive Officer, Sarah Boyce, our President; Jeff Goldberg, our Chief Operating Officer; and Mike MacLean, our Chief Financial Officer. As a reminder, this conference call includes forward looking statements regarding the financial outlook for Akcea's business and the therapeutic and commercial potential of Akcea's products and developments.

Any statements describing Akcea's goals, expectations, financial or other projection, intentions or believe including the commercial potential of TEGSEDI, WAYLIVRA and our pipeline drug is a forward-looking statement and should be considered as at-risk treatment. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Akcea's forward-looking statements also involve assumptions that if they never materialize or prove correct could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea's forward-looking statements reflects the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you're cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in Akcea's most recent quarterly report on Form 10-Q and in the most recent annual report on Form 10-K on file with the SEC. Copies of these and other documents are available from the company.

In addition earlier today, we issued a press release and related financial tables including a reconciliation of our GAAP to our reported non-GAAP financial measures that we will discuss today. To read this release and to keep up to date on our latest company news, please visit the Investor section of our website. Today, we also have slides to accompany our call. To access these slides and our press release, please visit the Investor section of our website.

Now I'll turn the call over to Paula.

Paula Soteropoulos

Thank you, Kath. Good afternoon, everyone, and thank you for joining us this afternoon. Reflecting on 2018, what a pivotal year it was for Akcea with the approval and launch of TEGSEDI in the US, Germany and Canada. We are now a global commercial company. Our track record of execution, broad pipeline, strategic partnership with Novartis and our foundational relationship with Ionis, provide a solid base for our future. In April, we completed the TTR franchise agreement with Ionis and with that we expanded our focus beyond the cardiometabolic because of the specialized rare disease capabilities that we built in the first three years since the company's inception, we